Novo Nordisk's Oral Wegovy Approved by FDA for Weight Loss

The U.S. FDA has approved Novo Nordisk's oral Wegovy (semaglutide 25 mg) for weight management and cardiovascular risk reduction, marking the first oral GLP-1 therapy for obesity. This offers a convenient alternative to injections, with a U.S. launch expected in early 2026.

• FDA approves Novo Nordisk's once-daily oral Wegovy (semaglutide 25 mg) for weight management.
• First oral GLP-1 receptor agonist specifically indicated for chronic weight management.
• Also approved to reduce major adverse cardiovascular events in at-risk adults.
• Clinical trials showed approximately 14-17% average weight loss, comparable to injectable Wegovy.
• U.S. launch of the oral pill is anticipated in early January 2026.
• Provides a convenient alternative for patients preferring pills over injections, potentially expanding market access.

Read the full story on Quick Digest.